AbbVie Presents New Late|Breaking Phase 2b Data on ...

AbbVie Presents New Late-Breaking Phase 2b Data on ...

In today's presentation, across all doses (30/15/7.5 mg once-daily), additional exploratory results showed significant reduction of select ...

7 - AbbVie News Center

AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting. - ...

AbbVie Presents New Late-Breaking Phase 2b Data on ...

Discovered and developed by AbbVie, upadacitinib is an investigational oral agent engineered to selectively inhibit JAK1, which plays an ...

AbbVie Provides Update on Phase 2 Results for Emraclidine in ...

In addition to emraclidine, through the Cerevel acquisition AbbVie gained a neuroscience pipeline of multiple clinical-stage and preclinical ...

News - AbbVie News Center

February 17, 2018. AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual ...

41 - AbbVie News Center

February 17, 2018. AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology ...

AbbVie News Center - News

All news · February 17, 2018. AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology ...

AbbVie Presents New Late-Breaking Data Analyses Showing ...

AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 ...

Abivax Provides Operational and Key Program Update

Phase 2 clinical trials in patients with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical ...

Release Details - Regenxbio Inc

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using ...

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II ...

12. AbbVie . A study comparing ABT‐494 to placebo in participants with active psoriatic arthritis who have a history of inadequate response to at least one ...

November 18, 2024 - AbbVie News Center

November 18, 2024. AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer.

AbbVie (ABBV) Presents New Late-Breaking Data Analyses ...

StreetInsider · AbbVie (ABBV) Presents New Late-Breaking Data Analyses Showing Risankizumab Achieves Clinical Remission and Endoscopic Response ...

AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI ...

AbbVie has shared new Phase 3 data analyses from the KEEPsAKE-1 and KEEPsAKE-2 studies, detailing the efficacy of risankizumab (SKYRIZI®) in treating adults ...

AbbVie Presents New Data from Antibody-Drug Conjugates Across ...

AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024 · PE: At this year's ASCO Annual Meeting, your ...

Guselkumab in Patients With Moderately to Severely Active ...

The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients ...

Press Release Details - Ironwood Pharmaceuticals, Inc.

Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure (SBS-IF) accepted as late-breaker oral presentation ...

AbbVie Showcases New, Late-Breaking Investigational Data at ...

In the same session, AbbVie will also share results from a Phase 2b trial of upadacitinib, an investigational oral JAK1-selective inhibitor, ...

Clinical Trial News - BioPharma Dive

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn't best placebo in two Phase 2 trials. By Jacob Bell • Nov.

ABBV's Newly Added Parkinson's Disease Drug Meets Second ...

Earlier this year, AbbVie reported data from the late-stage TEMPO-3 study that evaluated the drug as an adjunctive therapy to levodopa in adult ...